LUGANO, Switzerland – The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting.
The scientific programme will cover the latest discoveries across the spectrum of lung cancer – from prevention, screening and early detection to personalised strategies to ensure better care for patients.
- New research on vaccines and management of lung cancer patients outside of the COVID-19 pandemic
- Applying artificial intelligence:
- To help guide diagnosis and treatment of special populations, such as the elderly
- To empower pathology and genomics and enable drug development
- Applying electronic surveillance to improve treatment outcomes and telescreening to facilitate prevention
- Emerging therapies for platinum resistant disease
- New molecular sub-types to enhance precision medicine
- “The tissue is (still) the issue” by Fred Hirsch, 2022 Heine H. Hansen Award recipient, 30 March 2022, 13:30-14:15 CEST
- “Lung cancer in 2030” by Pasi A. Jänne, 1 April 2022, 12:10-12:40 CEST
- “Value of pathological response as an endpoint” by William Travis, 1 April 2022, 14:30-15.00 CEST
The ELCC organisers welcome media interested in obtaining information and reporting on cancer issues. Only through the official accreditation process with the media registration form, accredited media representatives will be able to access scientific and educational sessions, e-posters, virtual exhibition and industry satellite symposia, Congress webcasts, as well as embargoed material.
ELCC Press Office
The ELCC Congress brings together some of the most important organisations in the field of thoracic oncology, with the scope of disseminating education through a multidisciplinary approach and improve the practice of lung cancer specialists worldwide. The ELCC Congress is organised by ESMO (European Society for Medical Oncology) and the IASLC (International Association for the Study of Lung Cancer), along with their partner societies ESTRO (European Society for Radiotherapy & Oncology), ESTS (European Society for Thoracic Surgeons) and ETOP (European Thoracic Oncology Platform).